Posted by Michael Wonder on 22 Aug 2018
PBAC Drug Utilisation Sub-Committee utilisation analysis - public release documents
22 August 2018 - The utilisation analysis public release documents from the February 2018 DUSC meeting are now available.
There are three reports from the February 2018 meeting:
- Metastatic colorectal cancer (bevacizumab, cetuximab and panitumumab)
- HER2 positive, metastatic breast cancer (trastuzumab, trastuzumab emtansine and pertuzumab)
- Cystic fibrosis (ivacaftor)
